体外杀菌活性的棘白菌素类药物对念珠菌属 metapsilosis 、 C. orthopsilosis 和 C. parapsilosis 通过时间杀死研究评估。
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.
机构信息
Unidad de Microbiología Experimental, Centro de Investigación, Hospital Universitario La Fe, Valencia. Spain.
出版信息
Antimicrob Agents Chemother. 2010 May;54(5):2194-7. doi: 10.1128/AAC.01538-09. Epub 2010 Feb 9.
Abstract
Anidulafungin, micafungin, and caspofungin in vitro activities against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis were evaluated by MICs and time-kill methods. All echinocandins showed lower MICs (mean MICs, 0.05 to 0.71 mg/liter) and the highest killing rates (-0.06 to -0.05 CFU/ml/h) for C. metapsilosis and C. orthopsilosis rather than for C. parapsilosis (mean MICs, 0.59 to 1.68 mg/liter). Micafungin and anidulafungin killing rates were greater than those determined for caspofungin. None of the echinocandins had fungicidal activity against C. parapsilosis.
摘要
对近平滑念珠菌、中间型念珠菌和副热带念珠菌进行 MIC 和时间杀伤方法评估，发现阿尼芬净、米卡芬净和卡泊芬净对近平滑念珠菌和中间型念珠菌的体外活性均较低（MIC 均值分别为 0.05 至 0.71 毫克/升），杀菌率最高（-0.06 至-0.05 CFU/ml/h），而对副热带念珠菌的活性则较低（MIC 均值分别为 0.59 至 1.68 毫克/升）。米卡芬净和阿尼芬净的杀菌率大于卡泊芬净。所有棘白菌素类药物对副热带念珠菌均无杀菌活性。
相似文献
1
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.
Antimicrob Agents Chemother. 2010 May;54(5):2194-7. doi: 10.1128/AAC.01538-09. Epub 2010 Feb 9.
2
Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity.
Rev Iberoam Micol. 2019 Jan-Mar;36(1):24-29. doi: 10.1016/j.riam.2018.12.001. Epub 2019 Mar 2.
3
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
Antimicrob Agents Chemother. 2009 Jul;53(7):3108-11. doi: 10.1128/AAC.00160-09. Epub 2009 Apr 20.
4
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
J Antimicrob Chemother. 2012 Sep;67(9):2195-202. doi: 10.1093/jac/dks180. Epub 2012 May 25.
5
In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.
Antimicrob Agents Chemother. 2015;59(6):3615-8. doi: 10.1128/AAC.04474-14. Epub 2015 Mar 23.
6
[Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
Pathol Biol (Paris). 2011 Feb;59(1):52-6. doi: 10.1016/j.patbio.2010.07.019. Epub 2010 Sep 15.
7
Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods.
J Antimicrob Chemother. 2013 Apr;68(4):864-8. doi: 10.1093/jac/dks489. Epub 2012 Dec 9.
8
Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades.
Diagn Microbiol Infect Dis. 2016 Oct;86(2):172-7. doi: 10.1016/j.diagmicrobio.2016.07.011. Epub 2016 Jul 12.
9
Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Clin Microbiol Infect. 2009 Mar;15(3):274-9. doi: 10.1111/j.1469-0691.2008.02660.x. Epub 2009 Feb 5.
10
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
J Clin Microbiol. 2008 Jan;46(1):150-6. doi: 10.1128/JCM.01901-07. Epub 2007 Nov 21.
引用本文的文献
1
In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in spp.
J Fungi (Basel). 2023 Dec 12;9(12):1188. doi: 10.3390/jof9121188.
2
Activity of Fenticonazole against and Bacterial Vaginitis Isolates Determined by Mono- or Dual-Species Testing Assays.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.02693-18. Print 2019 Jul.
3
Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis.
Rev Esp Quimioter. 2019 Apr;32(2):183-188. Epub 2019 Mar 8.
4
Candida parapsilosis: from Genes to the Bedside.
Clin Microbiol Rev. 2019 Feb 27;32(2). doi: 10.1128/CMR.00111-18. Print 2019 Mar 20.
5
Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.
Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638.
6
Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.
J Antimicrob Chemother. 2017 Aug 1;72(8):2368-2377. doi: 10.1093/jac/dkx116.
7
Caspofungin-Non-Susceptible Isolated from Onychomycosis in Iran.
Iran J Public Health. 2017 Feb;46(2):235-241.
8
High Recovery Rate of Non-albicans Candida Species Isolated From Burn Patients With Candidemia in Iran.
Jundishapur J Microbiol. 2015 Oct 24;8(10):e22929. doi: 10.5812/jjm.22929. eCollection 2015 Oct.
9
Dose escalation studies with caspofungin against Candida glabrata.
J Med Microbiol. 2015 Sep;64(9):998-1007. doi: 10.1099/jmm.0.000116. Epub 2015 Jun 30.
10
Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.
PLoS One. 2015 Jul 13;10(7):e0132730. doi: 10.1371/journal.pone.0132730. eCollection 2015.
本文引用的文献
1
Identification of pathogenic yeast species by polymerase chain reaction amplification of the RPS0 gene intron fragment.
J Appl Microbiol. 2010 Jun;108(6):1917-27. doi: 10.1111/j.1365-2672.2009.04595.x. Epub 2009 Oct 20.
2
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.
J Clin Microbiol. 2009 Oct;47(10):3170-7. doi: 10.1128/JCM.00942-09. Epub 2009 Aug 26.
3
Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.
J Clin Microbiol. 2009 Aug;47(8):2392-7. doi: 10.1128/JCM.02379-08. Epub 2009 Jun 3.
4
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
Antimicrob Agents Chemother. 2009 Jul;53(7):3108-11. doi: 10.1128/AAC.00160-09. Epub 2009 Apr 20.
5
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
6
Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis.
J Antimicrob Chemother. 2008 Dec;62(6):1466-8. doi: 10.1093/jac/dkn403. Epub 2008 Sep 28.
7
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
8
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.
J Clin Microbiol. 2008 Aug;46(8):2659-64. doi: 10.1128/JCM.00803-08. Epub 2008 Jun 18.
9
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12. doi: 10.1128/AAC.00262-08. Epub 2008 Apr 28.
10
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
Antimicrob Agents Chemother. 2008 Apr;52(4):1506-9. doi: 10.1128/AAC.01595-07. Epub 2008 Feb 19.
Zotero 插件